ClinicalTrials.gg
CompletedNCT01617460Updated Aug 6, 2024Results posted

A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder

A Phase 3 interventional study of Aripiprazole in Autistic Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 5 sites in Japan. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing aripiprazole in Autistic Disorder — none open to participants now, none under way, none of them phase 3. Aripiprazole · Autistic Disorder.

Enrollment
7th of 15
86 · median 81
Started
2012
with 1 other
Phase 3
7 of 15
none open now
Registered
12th of 15
by date
Lead sponsor
2 of 15
Otsuka Pharmaceutical Co., Ltd.

Among the 15 studies testing aripiprazole in Autistic Disorder, this one is the 7th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 3, and was the 12th registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

None of the 15 studies testing aripiprazole in Autistic Disorder is open now. The open studies under Autistic Disorder, anywhere →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing aripiprazole in Autistic Disorder as a file.
02

Study summary

The objective of this study is to investigate the safety and efficacy of aripiprazole orally administered over long term in subjects who complete a short-term treatment study of pediatric Autistic Disorder (031-11-002 study).

03

Conditions studied

  • Autistic Disorder

Browse trials for

Keywords

  • Autistic Disorder, children and adolescents
  • aripiprazole
  • Long-term safety study
  • children and adolescents
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient meets Autistic disorder diagnostic criteria defined in .
  • The patient has completed the 031-11-002 study (the patient has visited the hospital during week8)
  • Inpatient or outpatient status

Exclusion criteria

Exclusion Criteria:

  • The patient is currently diagnosed with another disorder on the autism spectrum in , including Asperger's, Rett's Disorder, PDD-NOS, Childhood Disintegrative Disorder, or Fragile-X Syndrome.
  • Patients who fall under a listed in the ABILIFY package insert
  • Others
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Aripiprazole

    administered orally once daily

    Drug: Aripiprazole

Interventions

  • Flexibly dose administered orally once daily

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline at the Final Assessment in Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score

    The ABC-J Irritability subscale consists of 15 items. Each item scores range from 0 to 3: 0 = No problem, 1 = Mild aberrant behavior, 2 = Moderate aberrant behavior, and 3 = Severe aberrant behavior. Individual scores were summed, therefore, the overall score range was between 0-45. Higher scores represent worse condition.

    Time frame: Baseline, the final administration

07

Results

Posted Oct 20, 2017

Participant flow

Participant flow — Overall Study
MilestoneAripiprazole
Started86
Completed46
Not completed40
Withdrew: Adverse event10
Withdrew: Physician decision16
Withdrew: Protocol violation5
Withdrew: Withdrawal by subject9

Outcome measures

PrimaryMean Change From Baseline at the Final Assessment in Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score

The ABC-J Irritability subscale consists of 15 items. Each item scores range from 0 to 3: 0 = No problem, 1 = Mild aberrant behavior, 2 = Moderate aberrant behavior, and 3 = Severe aberrant behavior. Individual scores were summed, therefore, the overall score range was between 0-45. Higher scores represent worse condition.

Time frame:
Baseline, the final administration
Reported as:
Mean · units on a scale
Mean Change From Baseline at the Final Assessment in Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score
units on a scaleAripiprazole
Mean Change From Baseline at the Final Assessment in Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score-3.2 ± 8.1

Adverse events

Collected over From the start date of investigational medicinal product (IMP) administration to date of the final examination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole—10/86 (11.6%)84/86 (97.7%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventAripiprazole
AutismNervous system disorders2/86
Adenoidal hypertrophyRespiratory, thoracic and mediastinal disorders2/86
MalaiseGeneral disorders1/86
Lymphadenitis bacterialInfections and infestations1/86
Hand fractureInjury, poisoning and procedural complications1/86
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/86
AgitationPsychiatric disorders1/86
Glomerulonephritis acuteRenal and urinary disorders1/86
Status asthmaticusRespiratory, thoracic and mediastinal disorders1/86
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders1/86
Most frequent other events
Showing 10 of 25
Most frequent other events
EventAripiprazole
NasopharyngitisInfections and infestations53/86
SomnolenceNervous system disorders28/86
InfluenzaInfections and infestations25/86
Weight increasedInvestigations21/86
VomitingGastrointestinal disorders12/86
GastroenteritisInfections and infestations10/86
Increased appetiteMetabolism and nutrition disorders10/86
Rhinitis allergicRespiratory, thoracic and mediastinal disorders9/86
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders9/86
Dental cariesGastrointestinal disorders8/86

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Aripiprazole
<=18 years86
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(years)Aripiprazole
Mean10.0 ± 3.0
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole
Female17
Male69
Region of Enrollment
Region of Enrollment(participants)Aripiprazole
Japan86
08

Study locations

5 sites
  • Chubu Region, Japan
  • Chugoku Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
09

References and documents

Publications

  • Ichikawa H, Hiratani M, Yasuhara A, Tsujii N, Oshimo T, Ono H, Tadori Y. An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan. Psychiatry Clin Neurosci. 2018 Feb;72(2):84-94. doi: 10.1111/pcn.12607. Epub 2017 Nov 8. PubMed 28941259 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2017, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2012
First posted
Jun 12, 2012
Start
Sep 2012
Primary completionActual
Oct 2016
CompletionActual
Oct 2016
Results first posted
Oct 20, 2017
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01617460
Responsible party
Sponsor
First posted
Jun 12, 2012
Start date
Sep 2012
Primary completion
Oct 2016
Completion
Oct 2016
Results posted
Oct 20, 2017
Last update
Aug 6, 2024

Study contacts

Hiroaki Ono, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion